Related references
Note: Only part of the references are listed.Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection
Vanessa Monteil et al.
EMBO MOLECULAR MEDICINE (2021)
Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis
Gianluigi Savarese et al.
EUROPEAN JOURNAL OF HEART FAILURE (2021)
Can ACEIs and ARBs be safely continued in COVID-19:- The Evidence is here at Last!
Uma Velupandian
HEART VIEWS (2021)
The COVID-19 pandemic: consequences for nephrology
Annette Bruchfeld
NATURE REVIEWS NEPHROLOGY (2021)
Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA
Alberto Ortiz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)
Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
Jordana B. Cohen et al.
LANCET RESPIRATORY MEDICINE (2021)
Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system
Man Lung Yeung et al.
CELL (2021)
Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction
Charalampos Loutradis et al.
JOURNAL OF HUMAN HYPERTENSION (2021)
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease Abstracts
[Anonymous]
KIDNEY INTERNATIONAL (2021)
Renin-angiotensin system blockade in the COVID-19 pandemic
Jordana B. Cohen et al.
CLINICAL KIDNEY JOURNAL (2021)
Changes in the respiratory function of COVID-19 survivors during follow-up: A novel respiratory disorder on the rise?
Afroditi K. Boutou et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2021)
Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19 A Systematic Review and Meta-analysis
Ranu Baral et al.
JAMA NETWORK OPEN (2021)
Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure
Maria Jose Soler et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
An Insight on Multicentric Signaling of Angiotensin II in Cardiovascular system: A Recent Update
Kanika Verma et al.
FRONTIERS IN PHARMACOLOGY (2021)
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial
Axel Bauer et al.
LANCET RESPIRATORY MEDICINE (2021)
Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial
Mariano Duarte et al.
ECLINICALMEDICINE (2021)
A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19
Michael A. Puskarich et al.
ECLINICALMEDICINE (2021)
Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis
Daniel R. Morales et al.
LANCET DIGITAL HEALTH (2021)
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
Haibo Zhang et al.
INTENSIVE CARE MEDICINE (2020)
Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS
Yushun Wan et al.
JOURNAL OF VIROLOGY (2020)
The Science Underlying COVID-19 Implications for the Cardiovascular System
Peter P. Liu et al.
CIRCULATION (2020)
A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications
Joseph A. Roche et al.
FASEB JOURNAL (2020)
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
Safiya Richardson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy
Giacomo Grasselli et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
Annemarie B. Docherty et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study
Christopher M. Petrilli et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou et al.
LANCET (2020)
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Lei Fang et al.
LANCET RESPIRATORY MEDICINE (2020)
Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic
Andrew M. South et al.
NATURE REVIEWS NEPHROLOGY (2020)
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19
Giuseppe Mancia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19
Harmony R. Reynolds et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Age and Multimorbidity Predict Death Among COVID-19 Patients Results of the SARS-RAS Study of the Italian Society of Hypertension
Guido Iaccarino et al.
HYPERTENSION (2020)
Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19
Shigeru Shibata et al.
HYPERTENSION RESEARCH (2020)
ACE2 as a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System
Veronique Michaud et al.
JOURNAL OF CLINICAL MEDICINE (2020)
COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network
Kazuomi Kario et al.
JOURNAL OF CLINICAL HYPERTENSION (2020)
Factors associated with COVID-19-related death using OpenSAFELY
Elizabeth J. Williamson et al.
NATURE (2020)
Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe
Kitty J. Jager et al.
KIDNEY INTERNATIONAL (2020)
Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure
Julio A. Chirinos et al.
HYPERTENSION (2020)
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology
Petar M. Seferovic et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
Lauren B. Arendse et al.
PHARMACOLOGICAL REVIEWS (2019)
Classical Renin-Angiotensin System in Kidney Physiology
Matthew A. Sparks et al.
COMPREHENSIVE PHYSIOLOGY (2014)
Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist
Roelie M. Woesten-van Asperen et al.
JOURNAL OF PATHOLOGY (2011)
Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan
Maria Jose Soler et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme
Jun Agata et al.
HYPERTENSION RESEARCH (2006)
Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors
CM Ferrario et al.
KIDNEY INTERNATIONAL (2005)
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
K Kuba et al.
NATURE MEDICINE (2005)
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2
CM Ferrario et al.
CIRCULATION (2005)